Paradigm Therapeutics Acquires Late Stage “Breakthrough Therapy” Designated Therapy for Treatment of All Subtypes of Epidermolysis Bullosa (EB)
(Adnkronos) – ‘Topical Therapy for Treating the Wounds and Lesions on the Entire Skin Surface’ MT PLEASANT, S.C., Aug. 22, 2023 /PRNewswire/ — Paradigm Therapeutics Inc., a biopharmaceutical company, today announced the
